In life, most of our cells experience a tremendous amount of turnover, on the order of billions every day. As cells age, they stop dividing in a process called senescence, which is a natural part of ...

Scientists from Duke University School of Medicine, the University of Texas Health Science Center at San Antonio (UT Health San Antonio), and the University of Arkansas have found a way to improve the ...

Elevated plasma levels of the fatty acid transporter, CD36, have been shown to constitute a novel biomarker for type 2 diabetes mellitus (T2DM). We recently reported such circulating CD36 to be ...

Oxidized LDL (OxLDL), a causal factor in atherosclerosis, induces the expression of heat shock proteins (Hsp) in a variety of cells. In this study, we investigated the role of CD36, an OxLDL receptor, ...

Preclinical data demonstrate enhanced efficacy of PLT012 in pMMR colorectal cancer models - Findings position CD36 as a promising metabolic checkpoint target in an underserved patient population DOVER ...

A study identifies metastasis-initiating cells through a specific marker, namely the protein CD36. This protein, which is found in the membranes of tumor cells, is responsible for taking up fatty ...

One of the most common causes of death in the developed world is a disease of the major arterial blood vessels that can cause heart attacks and stroke. A critical step in this disease (which is known ...

Metabolic Dysfunction-Associated Steatotic Liver Disease（MASLD） is characterized by excessive accumulation of lipids in hepatocytes and is closely associated with the rapid rise in insulin resistance, ...

Insulin resistance is mainly characteristic for type 2 diabetes, a common disorder that is also a potent risk factor for coronary heart disease. Genetic associations with type 2 diabetes have recently ...

DOVER, Del. & EPALINGES, Switzerland, December 15, 2025--(BUSINESS WIRE)--Pilatus Biosciences Inc., a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and ...

Recently, a study revealed that CD36 expression and palmitoylation are regulated by the tumor suppressor gene EVA1A in hepatocellular carcinoma, making it a key regulator of hepatic lipid metabolism.

DOVER, Del. & EPALINGES, Switzerland, April 08, 2026--(BUSINESS WIRE)--Pilatus Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies for ...